ImmunoGen, Inc.
ImmunoGen, Inc. (IMGN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMGN · as of Jun 9, 2026
Key Statistics
Explore ImmunoGen, Inc. Data
imgn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 22 · Buy rate: 27.3%
The IMGN analyst consensus is Hold, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month price target is $14.79, representing -52.65% downside from the current price of $31.23.
Competitors & Peers
imgn competitorsIMGN
ALPN
BPMC
CERE
ISEE
KRTXStock Performance
Full HistoryAbout ImmunoGen, Inc.
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mir…
what is immunogen, inc. · imgn stock overview · immunogen, inc. company profile · who is immunogen, inc. ceo · imgn NASDAQ · immunogen, inc. headquarters · immunogen, inc. business segments
About Stock Overview & Key Data
ImmunoGen, Inc. (IMGN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 17, 1989. As of the latest trading session, IMGN stock price is $31.23, with a market capitalization of $8.7B. The stock has returned +726.32% over the past 12 months and +5.31% year-to-date.
According to 22 Wall Street analysts, the consensus rating for ImmunoGen, Inc. stock is Hold, with an average 12-month price target of $14.79. In fiscal year 2022, ImmunoGen, Inc. reported revenue of $108.8M and net income of -$222.9M. For detailed data — including ImmunoGen, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, ImmunoGen, Inc. (IMGN) stock price is $31.23. The stock is traded on NASDAQ under the ticker symbol IMGN. The 52-week range is $3.61 – $31.25.